정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 926 | Recruiting | Pegylated Interferon Lambda for Treatment of COVID-19 Infection | COVID-19 | Drug: Lambda 180 mcg S.C | Phase 2 | Soroka University Medical Center | OTHER | 40 | All | 18 Years | Soroka UMC, Be'er Sheva, Israel |
| 925 | Terminated | Pegylated Interferon Lambda Treatment for COVID-19 | COVID | Drug: Pegylated interferon lambda | Phase 2 | Raymond Chung, Eiger BioPharmaceuticals | OTHER | 14 | All | 18 Years | Massachusetts General Hospital, Boston, Massachusetts, United States |
| 924 | Terminated | Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). | Cardiac Infarct | Drug: Pemziviptadil (PB1046) Drug: Low Dose (10 mg) Control |
Phase 2 | PhaseBio Pharmaceuticals Inc. | INDUSTRY | 54 | All | 18 Years ~ 85 Years | Baptist Health Research Institute, Jacksonville, Florida, United States Sarasota Memorial Hospital, Sarasota, Florida, United States The University of Kansas Medical Center, Kansas City, Kansas, United States Adventist Healthcare White Oak Medical Center, Silver Spring, Maryland, United States |
| 923 | Withdrawn | Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection. | COVID-19 | Biological: vaccine BCG Other: Placebo |
Phase 3 | Universidad de Antioquia | OTHER | 0 | All | 18 Years ~ 65 Years | Program for Research and Control in Tropical Diseases - PECET, Medellin, Antioquia, Colombia |
| 922 | Recruiting | Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic | Hypertension | Drug: Amlodipine | Phase 4 | Queen Mary University of London, Closed Loop Medicine Ltd, Innovate UK | OTHER | 1000 | All | 18 Years | Queen Mary University London, London, United Kingdom |
| 921 | Completed | Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction | Corona Virus Infection | Drug: Anakinra Drug: Tocilizumab |
Phase 2 | Hellenic Institute for the Study of Sepsis | OTHER | 102 | All | 18 Years | 2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece Intensive Care Unit, Ioannina University Hospital, Ioannina, Ioannina, Greece Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece 1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece Intensive Care Unit, "Latsio", Thriasio Elefsis General Hospital, Elefsina, Greece Intensive Care Unit, "Koutlimbaneio & Triantafylleio" Larissa General Hospital, Larissa, Greece Department of Internal Medicine, Larissa University Hospital, Larissa, Greece Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece |
| 920 | Completed | PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19 | COVID-19 | Biological: Convalescent plasma | Phase 2 | Universidad Peruana Cayetano Heredia | OTHER | 100 | All | 18 Years | Hospital Cayetano Heredia, Lima, Peru Hospital Nacional Hipolito Unanue, Lima, Peru |